• 1
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 143344.
  • 2
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 3
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 4
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 120717.
  • 5
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 241728.
  • 6
    Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Suppl. 1): 88102.
  • 7
    Shiffman ML, Esteban R. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? Liver Int 2012; 32(Suppl. 1): 5460.
  • 8
    Estrabaud E, Vidaud M, Marcellin P, et al. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 111025.
  • 9
    Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 101424.
  • 10
    Bronowicki J-P, Hezode C, Bengtsson L, et al. 100% SVR in IL28B SNP rs12979860 C/C patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. J Hepatol 2012; 56(Suppl.): S56.
  • 11
    Sulkowski MS, Shiffman ML, Afdhal NH, et al. HCV treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139: 160211.
  • 12
    Shiffman ML, Salvatori J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 3719.
  • 13
    Poordad FF, Lawitz EJ, Reddy KR, et al. Randomized trial comparing ribavirin dose reduction versus erythropoeitin for anemia management in previously untreated patients with chronic hepatitis C receiving Boceprevir plus Peginterferon/Riba. J Hepatol 2012; 56(Suppl.): S455.
  • 14
    Sulkowski M, Roberts S, Afdhal N, et al. Ribavirin Dose Modification in Treatment-naive and Previously Treated Patients who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies. J Hepatol 2012: 56 (Suppl.): S459S460.
  • 15
    Fried M, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: final analysis of the pillar phase 2b study. Hepatology 2011; 54(Suppl.): 101A.
  • 16
    Sulkowski M, Ceasu E, Asselah T, et al. Sustained virologic response and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV. J Hepatol 2011; 54(Suppl. 1): S27.
  • 17
    Sulkowski M, Bourliere M, Bronowicki J, et al. SILEN-C2: sustained virologic response and safety of BI201335 combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with non-response to P/R. J Hepatol 2011; 54(Suppl. 1): S30.
  • 18
    Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: Final SVR24 results of the ASPIRE trial. J Hepatol 2012; 56(Suppl.): S1–S2.
  • 19
    Kowdley KV, Lawitz E, Crespo I, et al. ATOMIC: 97% RVR for PSI-7977+ PEG/RBV X 12 week regimen in HCV GT1: An end to response-guided therapy? J Hepatol 2012; 56(Suppl.): S1.
  • 20
    Gane EJ, Stedman C, Anderson J, et al. 100% Rapid Virologic Response for PSI-7977+ Ribavirin in Genotype 1 Null Responders (ELECTRON): Early Viral Decline Similar to that Observed in Genotype 1 and Genotype 2/3 Treatment-naïve Patients. Presented at CROI 2012.
  • 21
    Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +/- ribavirin, in treatment-naïve patients with genotype-1 HCV infection: Interim results of SOUND-C2. J Hepatol 2012; 56(Suppl.): S45.
  • 22
    Poordad F, Lawitz E, Kowdley KV, et al. 12-Week Interferon-Free Regimen of ABT-450/r+ABT-333+Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders. J Hepatol 2012; 56(Suppl.): S459–S550.
  • 23
    Lawitz E, Poordad F, Kowdley KV, et al. A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV IL28B-CC Genotype-1-Infected Subject. J Hepatol 2012; 56(Suppl.): S7.
  • 24
    Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 8819.
  • 25
    Schreiber J, Moreno C, Garcia BG, et al. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment Pharmacol Ther 2012; 36: 35362.
  • 26
    Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 12434.
  • 27
    Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J Hepatol 2007; 46: S6.
  • 28
    Cheinquer H, Shiffman ML, Zeuzem S, et al. The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study. Hepatology 2011; 56(Suppl.): S156.
  • 29
    Gane EJ, Stedman CA, Hyland RH, et al. Once Daily PSI-7977 plus RBV: Pegylated interferon-Alfa not required for Complete Rapid viral response in Treatment-naive Patients with HCV GT2 or GT3. Hepatology 2011; 54 (Suppl.): 377A.
  • 30
    Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005; 9: 41126.
  • 31
    Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 52732.
  • 32
    Hezode C, Shiffman ML, Cooper C, et al. Ritonavir-boosted danoprevir plus Peg-IFNα-2a/ribavirin demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with HCV genotype 4 infection in the DAUPHINE study J Hepatology 2012; 56(Suppl.): 118A.
  • 33
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 82532.
  • 34
    Hoefs JC, Shiffman ML, Goodman ZD, et al. Rate of progression of hepatic fibrosis in patients with chronic hepatitis c: results from the HALT-C trial. Gastroenterology 2011; 141: 9008.
  • 35
    Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 242941.
  • 36
    Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 13848.
  • 37
    Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010; 10: 103.